Emerging Updates in Front-line Treatment Approach of DLBCL

Author(s):

David Miklos, MD,Haifaa Abdulhaq, MD

Matthew Matasar, MD and Nilajan Ghosh, MD, PhD, discuss first-line treatment strategies for DLBCL, including factors influencing treatment selection, unmet needs in first-line treatment options, the impact of the 2024 NCCN guideline updates, and practical guidance for community practitioners following insights from the POLARIX trial.

Now Viewing

EP: 1.Emerging Updates in Front-line Treatment Approach of DLBCL

Video content above is prompted by the following:

Discuss treatment strategies for newly diagnosed DLBCL.
- What factors are most important when selecting treatments for 1L DLBCL?
- What are unmet needs in 1L treatment options in DLBCL.
With the 2024 NCCN update concerning Pola+R-CHP in DLBCL, how is your standard approach to 1L treatment of DLBCL evolving?
- How does the prolonged follow-up from POLARIX change your view on how and when to use POLA+R-CHP?
- What advice would you give to community practitioners when using this style of treatment?